Compare DBVT & GFUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBVT | GFUZ |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | France | Canada |
| Employees | 90 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.2M | 687.0M |
| IPO Year | 2014 | 2025 |
| Metric | DBVT | GFUZ |
|---|---|---|
| Price | $9.02 | $4.24 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $36.51 | N/A |
| AVG Volume (30 Days) | ★ 300.2K | 97.8K |
| Earning Date | 10-28-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,636,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,837.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.77 | N/A |
| 52 Week Low | $8.63 | $4.60 |
| 52 Week High | $26.19 | $11.00 |
| Indicator | DBVT | GFUZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 26.25 |
| Support Level | $8.78 | N/A |
| Resistance Level | $12.41 | $6.34 |
| Average True Range (ATR) | 0.76 | 0.44 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 0.97 | 0.00 |
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.